Apoptosis Lecture Notes

Apoptosis

Learning Outcomes

  • Understand the importance of apoptosis in animal development and function.

  • Explain the intrinsic and extrinsic pathways that trigger apoptosis.

  • Know the three key classes of Bcl2 family proteins and their roles.

  • Understand how apoptosis can be dysregulated in cancer, with the example of Bcl2 in follicular lymphoma and its treatment.

Types of Cell Death

  • Apoptotic cells have an intact plasma membrane, distorted chromatin, and concentrated nuclei.

  • Necrotic cells appear to have exploded.

Apoptosis (Programmed Cell Death)

  • Apoptosis, or programmed cell death (PCD), is a normal process for eliminating unwanted cells.

  • Critical in embryonic development (e.g., removing skin between digits) and removing damaged cells.

  • An intracellular proteolytic cascade is activated, leading to:

    • Cell shrinkage and condensation.

    • Dissolution of the nuclear envelope.

    • Condensation and fragmentation of chromatin.

    • Collapse of the cytoskeleton.

    • Engulfment and destruction of the cell by phagocytosis (e.g., by a macrophage).

  • No leakage of cell contents, avoiding an inflammatory reaction.

Cell Survival Depends on Extracellular Signals

  • Cells require survival factors (e.g., growth factors) to avoid apoptosis.

  • Neurotrophin trophic factors provide survival signals for neurons.

  • Experiment:

    • Wild-type mice express NGF (nernerve growth factor) and NT-3 (neurotrophin 3) which generate motor, nociceptive, and proprioceptive neurons.

    • Knockout mice lacking NGF or TrkA receptor lack nociceptive neurons.

    • Mice without NT-3 or TrkC receptor lack proprioceptive neurons.

Apoptosis is Mediated by a Caspase Cascade

  • An apoptotic signal triggers the assembly of an adaptor-protein complex, recruiting monomers that dimerize, activating them through cleavage.

  • Initiator caspases (8 and 9) cleave and activate executor caspases (3, 6, and 7), coordinating the apoptosis program.

  • Executor caspases cleave multiple targets in a cascading, non-reversible event.

    • Nuclear lamin is cleaved by caspase 6.

    • Phospholipid transfer proteins are cleaved, exposing phosphatidylserine (“eat me” signal).

  • Caspases have a cysteine at their active site and cleave at specific aspartic acid sites.

  • Exist as inactive soluble monomers in the cytosol.

Apoptosis Acts via the Intrinsic or Extrinsic Pathways

  • Two main activation pathways activate initiator caspases:

    • Extrinsic pathway: signaled from outside the cell, activated by death receptors (e.g., TNF family) and Fas ligands.

    • Intrinsic (mitochondrial) pathway: signaled from mitochondria inside the cell.

  • The extrinsic pathway needs to overcome caspase inhibitors by recruiting the intrinsic pathway in some cell types.

The Extrinsic Pathway

  • Tumor necrosis factor (TNF) interacts with cells through TNF receptors (Fas death receptors), which are homotrimeric receptors that bind trimeric Fas ligands.

  • Binding clusters receptors, exposing death domains on receptor tails, which bind and cluster FADD (Fas-associated death domain).

  • Clustered FADD proteins recruit inactive, monomeric initiator caspase-8, which oligomerize, forming a large death-inducing signaling complex (DISC).

  • Activated caspase-8 cleaves itself to form mature, active caspase-8 dimers that activate downstream executioner caspases.

The Intrinsic or Mitochondrial Pathway

  • Activated from within the cell (e.g., developmental signals, DNA damage).

  • Depends on the release of proteins from the mitochondrial intermembrane space, especially cytochrome c.

  • Cytochrome c binds to Apaf1 (apoptotic protease activating factor 1), causing it to bind deoxy-ATP and oligomerize into a wheel-like heptamer.

  • The heptamer recruits inactive initiator caspase-9 monomers, forming an apoptosome.

  • Caspase-9 is activated by dimerization within the apoptosome and activates downstream executioner caspases.

Bcl2 Proteins are Critical Regulators of Apoptosis

  • The BH3 domain is shared by all Bcl2 family members and mediates interactions between pro-apoptotic and anti-apoptotic family members.

  • Three classes of mammalian Bcl2 family proteins:

    1. Anti-apoptotic Bcl2 family proteins (e.g., Bcl2) inhibit apoptosis by preventing Mitochondrial Outer Membrane Permeabilization (MOMP).

    2. Pro-apoptotic Bcl2 family effectors (e.g., Bax, Bak) induce MOMP by creating openings in the outer mitochondrial membrane.

    3. BH3-only proteins (e.g., Bim, Puma, Noxa) promote apoptosis by regulating the other two classes and link apoptotic stimuli to the intrinsic pathway.

How Pro- and Anti-Apoptotic Bcl2 Family Proteins Act

  • Anti-apoptotic proteins Bcl2 and BclxL are located on the outer mitochondrial membrane, preventing MOMP by binding to the BH3 domains of Bak and Bax, preventing their oligomerization.

  • When an apoptotic stimulus activates the intrinsic pathway, Bak and Bax are activated and trigger MOMP by aggregating into oligomers, allowing cytochrome c to escape.

Summary of the Extrinsic and Intrinsic Pathways

  • Caspase-8 is the key link between the extrinsic and intrinsic pathways.

  • When apoptosis fails (e.g., absence of caspase-8 or FADD), the necroptosis pathway can be activated, triggered by RIPK1 kinase.

  • This activates a chain of proteins that form oligomers in the plasma membrane, destabilizing it and inducing cell swelling and rupture.

How Survival Factors Inhibit Apoptosis

  • Some survival factors suppress apoptosis by stimulating the transcription of genes encoding anti-apoptotic Bcl2 family proteins (e.g., Bcl2 or BclxL).

  • Many activate RTKs and the protein kinase Akt/PKB, which phosphorylates and inactivates the pro-apoptotic BH3-only protein Bad.

  • When not phosphorylated, Bad promotes apoptosis by binding to and inhibiting anti-apoptotic Bcl2 family proteins (e.g., Bcl2).

  • Phosphorylated Bad dissociates, freeing Bcl2 to suppress apoptosis.

  • Akt can also suppress apoptosis by phosphorylating and inactivating transcription regulatory proteins that stimulate the transcription of genes encoding proteins that promote apoptosis, such as the BH3-only protein Bim.

Summary of Pathway Integration Regulating MOMP

  1. Growth factor inhibition of apoptosis.

  2. Absence of growth/survival factor promotes apoptosis.

  3. DNA damage or UV stimulates apoptosis.

Apoptosis is Triggered by a Variety of Pathways

  • Apoptosis can be activated by direct signaling or activation of DNA damage pathways.

  • It can also occur if critical survival factors (e.g., growth factors) are withdrawn from the cell.

Excess or Insufficient Apoptosis Can Cause Disease

  • Conditions such as heart attack and stroke can lead to initial cell death by necrosis, with subsequent apoptosis in the affected area.

  • Mutations in the Fas receptor or ligand prevent normal lymphocyte death, leading to an excess in lymph nodes and spleen, triggering autoimmune disorders and lymphomas.

  • Decreased rates of apoptosis are important factors in many cancers, as normal inhibitory controls on apoptosis are defective in cancer cells.

Dysregulated Apoptosis and Cancer

  • Resistance to apoptosis is one of the hallmarks of cancer.

  • Mechanisms by which evasion of apoptosis occurs:

    1. Disrupted balance of pro-apoptotic and anti-apoptotic proteins.

    2. Reduced caspase function.

    3. Impaired death receptor signaling.

Tumour Cells are Frequently Resistant to Fas-Induced Apoptosis

  • Decreased receptor expression.

  • Expression of soluble Fas.

  • Increased expression of c-FLIP.

  • Decreased expression of caspase-8.

  • Increased expression of bcl-2 and/or decreased bax/bad/bak.

  • Defects in signaling and gene expression which may potentiate any/all of these effects.

Dysregulated Apoptosis and Haematopoietic Cancers

  • A disrupted balance of pro-apoptotic and anti-apoptotic proteins plays a role in many cancers of the blood and lymphoid tissues (leukemias and lymphomas).

  • In chronic lymphocytic leukemia (CLL), malignant cells have an anti-apoptotic phenotype with high levels of anti-apoptotic Bcl-2 and low levels of pro-apoptotic proteins such as Bax, so leukemogenesis is due to reduced apoptosis rather than increased proliferation.

  • The BCL2 (B cell lymphoma 2) gene was first identified because of the t(14; 18) chromosome translocation (present in >90% of follicular B cell lymphomas), resulting in overexpression of Bcl2 and inhibition of apoptosis.

  • Mcl1 (myeloid leukemia 1) is another commonly expressed pro-survival protein in hematological malignancies.

Therapy: Venetoclax Inhibits Bcl2

  • Drugs have been developed to block the anti-apoptotic proteins Bcl2 and BclXL by binding with high affinity to the BH3-binding groove.

  • These BH3 mimetic drugs stimulate the intrinsic pathway of apoptosis, particularly in cells that are heavily dependent on a particular anti-apoptotic Bcl2 family member for their survival.

  • Venetoclax binds to Bcl2 and is used effectively in chronic lymphocytic leukemia.

Bcl2 and Mcl1 Inhibitors for Haematological Cancers

  • BAX/BAK are essential to drive MOMP and are required for the action of venetoclax and all BH3 mimetics.

  • In normal plasma cells and in many cases of multiple myeloma (MM), the predominant survival protein expressed is MCL1. MCL1 inhibition could prove effective for this plasma cell malignancy.

  • Some subtypes of multiple myeloma are also highly susceptible to BCL2 inhibition.

  • In acute myeloid leukemia (AML), the degree of dependence on BCL2 or on MCL1 varies, with some subtypes being more BCL2 reliant than others.

  • Overall, both BCL2 and MCL1 appear to play prominent pro-survival roles in most AML cases.

Cancer Therapeutic Approaches Targeting Apoptosis

  • Examples include DRL, TRAIL, Mapatumumab, Apo2L/TRAIL, TLY012, ABBV-621, GEN1029, conatumumab, ONC201, and MM-201.

  • Growth factor receptors and dopamine receptors (DRD2 & DRD3) are also targets.

  • BH3 mimetics such as Venetoclax, S55746, and APG-2575.

  • Other approaches target MDM2, p53, IAP, and ER stress.